Your browser doesn't support javascript.
loading
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
Rhanine, Yasmine; Bonnefoi, Hervé; Goncalves, Anthony; Debled, Marc; Le Moulec, Sylvestre; Bonichon, Nathalie; Macgrogan, Gaetan; Arnedos, Monica; Dubroca-Dehez, Bénédicte; Grellety, Thomas.
Affiliation
  • Rhanine Y; Medical Oncology Department, Institut Bergonié, Bordeaux, France.
  • Bonnefoi H; Medical Oncology Department, Institut Bergonié and Université de Bordeaux, UFR Sciences Médicales, Bordeaux, France.
  • Goncalves A; Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
  • Debled M; Medical Oncology Department, Institut Bergonié, Bordeaux, France.
  • Le Moulec S; Medical Oncology Department, Polyclinique Marzet, Pau, France.
  • Bonichon N; Medical Oncology Department, Clinique Tivoli, Bordeaux, France.
  • Macgrogan G; Pathology Department, Institut Bergonié, Bordeaux, France.
  • Arnedos M; Medical Oncology Department, Institut Bergonié, Bordeaux, France.
  • Dubroca-Dehez B; Medical Information Department, Centre Hospitalier de la Côte Basque, Bayonne, France.
  • Grellety T; Medical Oncology Department, Centre Hospitalier de la Côte Basque, Bayonne, France. Electronic address: tgrellety@ch-cotebasque.fr.
Breast ; 73: 103667, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38160476
ABSTRACT
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Triple Negative Breast Neoplasms / Androgen Antagonists Limits: Humans Language: En Journal: Breast Journal subject: ENDOCRINOLOGIA / NEOPLASIAS Year: 2024 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Triple Negative Breast Neoplasms / Androgen Antagonists Limits: Humans Language: En Journal: Breast Journal subject: ENDOCRINOLOGIA / NEOPLASIAS Year: 2024 Type: Article Affiliation country: France